U.S. Markets closed

Qnexa news sends Vivus through roof

Jon "DRJ" Najarian (ask-drj@optionmonster.com)

Shares More Than Double On Key Panel Vote

Vivus has been a lively stock, but this morning it's on fire after a U.S. Food & Drug Administration panel recommended approval of its Qnexa obesity drug. VVUS up more than 100 percent in the premarket! Arena Pharmaceuticals and Orexigen Therapeutics, which are working on a similar treatments, surged about 20 percent as well.

Forecast Drags on Limited Shares

Limited Brands reported better-than-expected earnings and revenue for the fourth-quarter, but predicted first-quarter profit of just $0.35 to $0.40. Analysts had expected $0.44. Guidance for the full year was also light, and LTD is down 3 percent in the premarket.

Strong Results Lift Hansen Medical

Hansen Medical reported a fourth-quarter loss of $0.16 a share, $0.01 narrower than analysts had feared. Revenue also beat consensus, sending HNSN higher by 8 percent in the pre.

More From optionMONSTER